1034297-84-1

Basic information

• Product Name: 5-bromo-3-(3-methoxyphenyl)-2-pyridinamine
• Synonyms: 5-bromo-3-(3-methoxyphenyl)-2-pyridinamine
• CAS NO: 1034297-84-1
• Molecular Weight: 279.136
• Mol File: 1034297-84-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-bromo-3-(3-methoxyphenyl)-2-pyridinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-(3-methoxyphenyl)-2-pyridinamine(1034297-84-1)
• EPA Substance Registry System: 5-bromo-3-(3-methoxyphenyl)-2-pyridinamine(1034297-84-1)

Safety Data

• Hazardous Substances Data: 1034297-84-1(Hazardous Substances Data)

Upstream product

• 381233-96-1 2-amino-3-iodo-5-bromopyridine 
• 10365-98-7 3-methoxyphenylboronic acid 

Downstream Products

• 1034297-85-2 [5-bromo-3-(3-methoxyphenyl)-pyridin-2-yl]methylamine 

Relevant articles and documents

Selectfluor-promoted regioselective chlorination/bromination of 2-aminopyridines and 2-aminodiazines using LiCl/LiBr

Using LiCl as a chlorine source, the chlorination of 2-aminopyridines or 2-aminodiazines in the presence of Selectfluor and DMF is established under mild conditions. This method gives chlorinated pyridines or diazines in good to high yields with high regioselectivities. Also, this method is extended to the bromination of 2-aminopyridines or 2-aminodiazines by using LiBr. The regioselectivity of the chlorination reaction is strongly dependent upon the substituent pattern in either the 2-aminopyridines or 2-aminodiazines. The synthesis of Buparlisib from chlorinated pyridines was explored. A study of the mechanism revealed that this chlorination occurs via either a pyridine or diazine radical process.

PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS

The present invention pertains generally to the field of therapeutic compounds,. arid more specifically to certain pyridine benzamide and pyrazine benzamide compounds (I) (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD1 that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.